Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body’s ability to rebuild and repair its own cells and tissues, today announced that senior management will participate in two upcoming healthcare investor conferences in June.
Conference Details: | |||
Event: | Jefferies 2016 Healthcare Conference | ||
Date/Time: | June 8, 2016 at 3:30 p.m. EDT | ||
Location: | New York, NY | ||
Event: | JMP Securities Life Sciences Conference | ||
Date/Time: | June 21, 2016 at 3:30 p.m. EDT | ||
Location: | New York, NY | ||
Live audio webcasts for both conferences will be available on the "Events and Presentations" page in the Investors section on the Company's website (www.acceleronpharma.com). A replay of the webcasts will also be available on Acceleron's website.
About Acceleron
Acceleron discovers and develops novel therapies to treat a wide range of rare diseases. Its pioneering research platform leverages the powerful biology behind the body’s ability to rebuild and repair its own cells and tissues. This innovative approach to drug discovery has generated four therapeutic candidates currently in clinical trials. The Company’s lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases, myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.
For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160601005420/en/
Contacts:
Todd James, IRC, 617-649-9393
Senior
Director, Investor Relations and Corporate Communications
or
Media:
BMC
Communications LLC
Brad Miles, 646-513-3125